Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | F2 | P00734 | 3/20 | 0.35 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.31 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.30 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6468944 | 0.78 | SIRT6 (0.44) | KMT2AOPRM1OPRK1 | |
| SCHEMBL5132531 | 0.78 | MEN1 (0.42) | MEN1KMT2AF2 | |
| SCHEMBL6468988 | 0.78 | TLR7 (0.44) | MEN1KMT2AF2 | |
| SCHEMBL13412486 | 0.77 | NUDT1 (0.43) | MEN1KMT2ANUDT1KDM4EHSD17B10 | |
| SCHEMBL6470756 | 0.75 | MEN1 (0.40) | MEN1KMT2AF2 | |
| SCHEMBL6468950 | 0.74 | MEN1 (0.44) | MEN1KMT2AF2OPRM1OPRK1 | |
| SCHEMBL807843 | 0.72 | MEN1 (0.49) | MEN1KMT2AF2 | |
| SCHEMBL11523536 | 0.72 | MEN1 (0.38) | MEN1KMT2ANUDT1KDM4EHSD17B10 | |
| SCHEMBL6193695 | 0.69 | POLB (0.39) | NUDT1HSD17B10 | |
| SCHEMBL17282054 | 0.68 | CHRM2 (0.62) | MEN1KMT2AKDM4ESIRT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050107381-A1 | 6-membered heteroaryl compounds for the treatment of neurodegenerative disorders | PFIZER, INC. | 2005-05-19 | — | — | US | claimed |
| US-20050107381-A1 | 6-membered heteroaryl compounds for the treatment of neurodegenerative disorders | PFIZER, INC. | 2005-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050107381-A1 | 6-membered heteroaryl compounds for the treatment of neurodegenerative disorders | APP, BACE1, SNCA | MEN1 978/4885KMT2A 2085/4885F2 1581/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.